Pricing pressure in established biosimilars
Core EBITDA growth lagged revenue growth in FY25 due to pricing pressure on existing products; management acknowledged this but expects improvement from new launches.
medium · management_commentaryBiocon Limited — Q4 FY25
Biocon delivered a strong Q4 FY25 with consolidated revenue of INR 4,417 crore, up 15% YoY on a like-for-like basis, driven by generics (+46% YoY) and biosimilars (+9% YoY).
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Lumpy generic revenue from lenalidomide
Q4 generics revenue was boosted by launch supplies of lenalidomide; volumes will be limited until patent expiry in January 2026, creating revenue lumpiness.
medium · management_commentaryAdalimumab US market share stagnation
Biosimilar Adalimumab has not gained expected share due to originator staying on formularies; management expects improvement but no specific timeline.
medium · analyst_questionHigh debt and structured instrument obligations
Net debt at Biocon Biologics is ~$1.1B; capital raise is intended to address put options, but not all investors may exercise, leaving residual obligations.
high · analyst_question